Pharmacogenetics in health-care practice

[1] Beijer HJ(2002)Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies Pharm World Sci 24 46-54

[2] de Blaey CJ.(1998)Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1200-5

[3] Lazarou J(1999)Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56 247-58

[4] Pomeranz BH(1999)Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology Ann Clin Biochem 36 722-9

[5] Corey PN.(1998)Pharmacogenomics-it's not just pharmacogenetics Curr Opin Biotechnol 9 595-601

[6] Nebert DW(1990)Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations Eur J Clin Pharmacol 39 533-7

[7] van der Weide J(1997)Non-functional CYP2D6 alleles and risk for neurolep-tic-induced movement disorders in schizophrenic patients Psy-chopharmacology (Berl) 131 174-9

[8] Steijns LS.(2002)Leufkens HGM. Antipsychotic-induced extrapyrimi-dal syndromes and cytochrome P450-2D6 genotype Pharma-cogenetics 12 235-40

[9] Bailey D(2000)Genetic poly-morphism of thiopurine methyltransferase and its clinical rele-vance for childhood acute lymphoblastic leukemia Leukemia 14 567-72

[10] Bondar A(2004)Clinical utility of thiopurine s-methyl-transferase genotyping Am J Pharmacogenomics 4 1-8

[1] Beijer HJ(2002)Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies Pharm World Sci 24 46-54

[2] de Blaey CJ.(1998)Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1200-5

[3] Lazarou J(1999)Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56 247-58

[4] Pomeranz BH(1999)Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology Ann Clin Biochem 36 722-9

[5] Corey PN.(1998)Pharmacogenomics-it's not just pharmacogenetics Curr Opin Biotechnol 9 595-601

[6] Nebert DW(1990)Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations Eur J Clin Pharmacol 39 533-7

[7] van der Weide J(1997)Non-functional CYP2D6 alleles and risk for neurolep-tic-induced movement disorders in schizophrenic patients Psy-chopharmacology (Berl) 131 174-9

[8] Steijns LS.(2002)Leufkens HGM. Antipsychotic-induced extrapyrimi-dal syndromes and cytochrome P450-2D6 genotype Pharma-cogenetics 12 235-40

[9] Bailey D(2000)Genetic poly-morphism of thiopurine methyltransferase and its clinical rele-vance for childhood acute lymphoblastic leukemia Leukemia 14 567-72

[10] Bondar A(2004)Clinical utility of thiopurine s-methyl-transferase genotyping Am J Pharmacogenomics 4 1-8